SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 18.08 |
| Enterprise Value ($M) | 12.64 |
| Book Value ($M) | 4.96 |
| Book Value / Share | 0.53 |
| Price / Book | 3.64 |
| NCAV ($M) | 4.96 |
| NCAV / Share | 0.53 |
| Price / NCAV | 3.65 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.41 |
| Return on Assets (ROA) | -0.91 |
| Return on Equity (ROE) | -1.03 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 9.43 |
| Current Ratio | 9.43 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 5.55 |
| Assets | 5.55 |
| Liabilities | 0.59 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -7.24 |
| Net Income | -6.99 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -5.61 |
| Cash from Investing | 0.00 |
| Cash from Financing | 8.42 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Empery Asset Management, LP | 4.99 | -46.82 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 19,017 | 135,880 | 14.00 | |
| 16,854 | 161,047 | 10.47 | |
| 40,076 | 82,468 | 48.60 | |
| 42,852 | 144,372 | 29.68 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BCDA – BioCardia, Inc. | BCLI – Brainstorm Cell Therapeutics Inc. |
| BCTX – BriaCell Therapeutics Corp. | BFRI – Biofrontera Inc. |
| BGM – BGM Group Ltd. |
Financial data and stock pages provided by
Fintel.io